← 返回

食管鳞状细胞癌的免疫逃逸:肿瘤微环境视角

英文原题:Immune evasion in esophageal squamous cell cancer: From the perspective of tumor microenvironment.

查看英文原题

Immune evasion in esophageal squamous cell cancer: From the perspective of tumor microenvironment.

PubMed 2023/01/09(内容时间) Front Oncol Q2 · IF 3.4(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

食管癌是全球威胁生命最严重的恶性肿瘤之一。食管鳞状细胞癌(ESCC)是其主要亚型,每年约占新发食管癌的90%。尽管多学科治疗策略迅速发展,ESCC患者常在晚期确诊,长期预后仍不理想。近几十年来,免疫检查点抑制剂、肿瘤疫苗和CAR-T 细胞疗法等免疫疗法已成功用于临床肿瘤治疗,为ESCC患者带来新希望。

然而,由于原发性或获得性耐药,只有少数患者获得临床获益。免疫逃逸在ESCC发生和进展中发挥关键作用。因此,充分理解ESCC细胞逃避免疫抗肿瘤作用的机制,是制定更有效多学科治疗策略的必要前提。研究已广泛认识到,免疫逃逸与肿瘤细胞和肿瘤微环境(TME)之间的相互作用密切相关。TME是动态、复杂且综合的系统,不仅包含细胞成分,也包含非细胞成分;这些因素从肿瘤外部影响肿瘤细胞的特征和命运。靶向有利于肿瘤生长的TME的新型免疫疗法,是改善ESCC患者治疗反应的有前景策略。本综述概述ESCC免疫逃逸,主要聚焦TME参与ESCC免疫逃逸的分子机制,并讨论靶向TME开展ESCC精准治疗的挑战与机遇。

展开英文摘要原文

Esophageal cancer (EC) is one of the most life-threatening malignancies worldwide. Esophageal squamous cell carcinoma (ESCC) is the dominant subtype, accounting for approximately 90% of new incident EC each year. Although multidisciplinary treatment strategies have advanced rapidly, patients with ESCC are often diagnosed at advanced stage and the long-term prognosis remains unsatisfactory.

In recent decades, immunotherapy, such as immune checkpoint inhibitors (ICIs), tumor vaccines, and chimeric antigen receptor T-cell (CAR-T) therapy, has been successfully used in clinical practice as a novel therapy for treating tumors, bringing new hope to ESCC patients.

However, only a small fraction of patients achieved clinical benefits due to primary or acquired resistance. Immune evasion plays a pivotal role in the initiation and progression of ESCC.

Therefore, a thorough understanding of the mechanisms by which ESCC cells escape from anti-tumor immunity is necessary for a more effective multidisciplinary treatment strategy. It has been widely recognized that immune evasion is closely associated with the crosstalk between tumor cells and the tumor microenvironment (TME).

TME is a dynamic complex and comprehensive system including not only cellular components but also non-cellular components, which influence hallmarks and fates of tumor cells from the outside. Novel immunotherapy targeting tumor-favorable TME represents a promising strategy to achieve better therapeutic responses for patients with ESCC. In this review, we provide an overview of immune evasion in ESCC, mainly focusing on the molecular mechanisms that underlie the role of TME in immune evasion of ESCC.

In addition, we also discuss the challenges and opportunities of precision therapy for ESCC by targeting TME.

论文信息

作者
Li R、Huang B、Tian H、Sun Z
单位
Department of Thoracic Surgery, Qilu Hospital of Shandong University, Jinan, Shandong, China.China
文献类型
综述
期刊
Frontiers in oncology2022
原文标识
PubMed 36698392 · DOI 10.3389/fonc.2022.1096717